Medical Professionals

MitoPrime’s API, L-ergothioneine, is being used, or seriously investigated, for the following conditions:

Cardiovascular health
Neuro-degenerative diseases
Ocular health
Kidney health
Lung function
Obesity
Type II diabetes
PTSD

Mitochondrial diseases
Cancer
Immune diseases
Anxiety
OCD
Parkinson’s disease
Huntington’s disease
COPD

Relevant New Published Study

Could Ergothioneine Aid in the Treatment of Coronavirus Patients?

Could Ergothioneine Aid in the Treatment of Coronavirus Patients?
Received: 4 June 2020; Accepted: 2 July 7, 2020; Published: 7 July, 2020

Extreme viruses, such as COVID-19, often leave their mark long after a person has recovered. Especially vulnerable are the heart, lungs, and brain. MitoPrime’s active, L-ergothioneine, helps in both underlying conditions and after effects.

MitoPrime and the Lungs

Studies show that MitoPrime (ergothioneine, in the optimized form) protects lungs by inhibiting pulmonary epithelial-mesenchymal transition, a key event in pulmonary fibrosis. Interestingly, MitoPrime (ergothioneine) also has the ability to protect the lung’s epithelial cells from the damaging effects of cigarette smoke.

MitoPrime and the Brain

COVID-19 can lead to lasting neurological (nerve system) symptoms in the brain, especially as it affects the thalamus, cerebrum, and brainstem. But research says MitoPrime’s (ergothioneine) neuro-protective properties may offer major help.

The study cites research proving that ergothioneine protects against a range of neurotoxins, such as amyloid and cisplatin. And researchers are quick to point out that people with mild cognitive impairment exhibit significantly lower blood levels of ergothioneine. This all suggests that ergothioneine may be a valuable asset in dealing with the potential residual conditions caused by extreme viruses.

MitoPrime and the Heart

Two new studies from Germany show that Covid-19 can cause long-term damage to the heart, even if the illness was not severe enough to require patient hospitalization.

MitoPrime’s natural cardio-protective/restorative capability during cardiac ischaemia-reperfusion offers hope.

MitoPrime (ergothioneine) counters the harmful oxidation of myoglobin, helping to prevent damage to the heart muscle. This suggests that MitoPrime may have the ability to protect the heart following infection by coronavirus.